Tesevatinib: Phase II started

Kadmon began an open-label, U.S. Phase II trial to evaluate 300 mg oral tesevatinib once daily in up to 40 patients with recurrent glioblastoma. Kadmon has rights to tesevatinib under a 2010 deal with...